Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert J. Pignolo has a total of 373 co-authors. Here are the top co-authors by number of shared publications:

  • Frederick S. Kaplan

    Departments of Orthopaedic Surgery and Medicine, Center for Research in FOP and Related Disorders, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA 19104

    34 shared publications
  • Abhishek Chandra

    Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA

    13 shared publications
  • Sundeep Khosla

    Department of Physiology and Biomedical Engineering Mayo Clinic Rochester Minnesota USA

    12 shared publications
  • David G. Monroe

    Division of Endocrinology, Mayo Clinic, Rochester, USA

    9 shared publications
  • Edward C. Hsiao

    Division of Endocrinology and Metabolism, the UCSF Metabolic Bone Clinic, the Eli and Edyth Broad Institute for Regeneration Medicine, and the Institute of Human Genetics, Department of Medicine, and the UCSF Program in Craniofacial Biology, University of California San Francisco , San Francisco, CA 94143

    9 shared publications
  • Frederick S. Kaplan

    Departments of Orthopaedic Surgery & Medicine, The Center for Research in FOP and Related Disorders, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

    8 shared publications

Latest Publications

  • Dual-Energy X-Ray Absorptiometry–Derived Body Composition Asymmetry in Pain-Free Adults

    by Soumyadip Sen, Apurba Barman, Yalda Nikanpour, Saman Toutounchi, Orod Gharibi, Dk Kim, Lichun Lu, Kenton Kaufman, Robert Pignolo, Asghar Rezaei

    Objective: To characterize body composition asymmetry in asymptomatic adults and examine its associations with age, lumbar intervertebral disc degeneration (DD), and physical activity. Design: Dual-energy X-ray absorptiometry scans were performed, and lumbar DD grading, and physical activity levels were assessed in clinically asymptomatic adults in this cross-sectional study. Results: Fifty-one participants were included. Asymmetry in trunk fat and lean tissue mass was present in the overall cohort ( P P =0.0178), with right-sided predominance in older participants ( P =0.0094). Trunk lean AI (TLAI) was higher in older than younger participants (6.3±4.9 vs. 3.5±2.6; P =0.012), whereas the corresponding trunk fat AI (TFAI) difference was not statistically significant (8.0±5.9 vs. 5.0±3.6; P =0.085). Greater age was associated with TLAI ( P =0.008), while the trunk fat association was less robust in sensitivity analyses. Signed TFAI and TLAI shifted toward non-dominant-side predominance with greater age ( P <0.05). Lumbar DD and physical activity were not significantly associated with asymmetry. Conclusion: Body composition asymmetry was most evident in the trunk. Trunk lean asymmetry was greater at older ages, whereas the corresponding trunk fat association was weaker. Because functional outcomes were not assessed, the clinical significance of these findings requires further investigation.

  • Open Access

    Palovarotene impact on fibrodysplasia ossificans progressiva (FOP): data from month 48 of the phase III MOVE trial

    by Robert J Pignolo, Edward C Hsiao, Mona Al Mukaddam, Geneviève Baujat, Staffan K Berglund, Angela M Cheung, Carmen De Cunto, Patricia Delai, Nobuhiko Haga, Peter Kannu, et al.

    Palovarotene is approved in several countries for reducing heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare, severely debilitating, genetic disorder. Approval was based on interim phase III MOVE trial (NCT03312634) analyses at month 18 (IA3), the most complete dataset considering subsequent clinical holds for futility and study restart; however, long-term data remain limited. We report exploratory, post hoc analyses of once daily palovarotene over the 48-mo MOVE trial, including time on and off treatment. The primary efficacy outcome was annualized change in new HO volume, per low-dose whole-body CT. Safety was assessed throughout. Post-baseline HO volume measurements were available for 97 palovarotene-treated patients from MOVE and 101 untreated patients from a natural history study (NHS; NCT02322255). Across 48 mo, mean annualized new HO volume was numerically lower (46.4%) in palovarotene-treated patients compared with untreated patients; however, this difference was not significant (nominal p = .0585). In patients who paused and stopped or paused and restarted palovarotene, mean annualized new HO volume appeared lower when patients received palovarotene compared with when they did not (significance not assessed). The proportions of patients with new HO and number of affected body regions were similar in palovarotene-treated patients and untreated patients (significance not assessed); flare-up rates were consistent with published literature. Adverse events were predominantly retinoid-associated mucocutaneous events. In 80 patients aged <18 yr in MOVE, palovarotene treatment occurred for a mean (SD) of 166.0 (75.2) wk; 24 (30.0%), all aged <14 yr, had premature physeal closure events. Computational analyses showed a significantly increased risk of radiographically-observed, asymptomatic new-onset vertebral deformities with palovarotene treatment. Overall, these exploratory analyses reaffirm the MOVE IA3 findings but should be interpreted with caution; potential efficacy must be weighed against the safety profile of palovarotene, particularly in growing patients. Clinical trial registration number: NCT03312634 (MOVE), NCT02322255 (NHS), and NCT02279095 (phase II OLE).


  • Open Access

    BCX9250 is a potent small-molecule inhibitor of Activin A Receptor Type 1 (ACVR1/ALK2) for fibrodysplasia ossificans progressiva

    by Haitao Wang, Saman Toutounchi, Robert J Pignolo, Xiaogang Cheng, Cynthia Davis Parker, Qingde Liu, Saritha Muppa, Debra Kellogg-Yelder, Kevin J Polach, Pravin L Kotian, et al.

    Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disease of heterotopic ossification (HO) caused by mutations in the activin receptor-like kinase-2 (ALK2) protein, a BMP type I receptor of the TGF-β superfamily. These mutations in the ALK2 receptor alter receptor function, causing activin A, a protein that normally inhibits ALK2 signaling, to aberrantly trigger suppressor of mothers against decapentaplegic 1/5/8 (SMAD1/5/8) signaling, thereby activating the chondroosteogenic pathway and leading to HO. Here we report the initial characterization of BCX9250, an orally available small-molecule inhibitor of ALK2 developed by BioCryst with the potential to treat FOP. Inhibition of ALK2-mediated signaling by BCX9250 was assessed using biochemical binding assays and in vitro activity assays with the mouse myoblast C2C12 cell line. The impact of BCX9250 on HO was investigated using 2 mouse models and an HO recurrence mouse model. BCX9250 has potent inhibitory activity against wild-type ALK2 protein and mutant ALK2 protein associated with FOP. In the ALK2R206H-expressing C2C12 cells, BCX9250 potently inhibited activin A-induced SMAD1 phosphorylation. In the selectivity assays, BCX9250 also potently inhibited several other protein kinases. Oral delivery of BCX9250 significantly reduced HO in 2 mouse models, including the Acvr1R206H knock-in mouse FOP model. BCX9250 also reduced the recurrence of HO after surgical removal of HO, suggesting that ALK2 inhibitors may be beneficial as prophylactic treatments following surgical excision of HO. These results suggest that BCX9250 may be useful for the treatment of FOP.

  • Open Access

    Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage

    by David Achudhan, Jacob Orme, Ritika Sharma, Aqsa Komel, Khubaib Gul Khan, Thomas A White, Nathan K LeBrasseur, Sundeep Khosla, Sean S Park, Robert J Pignolo, et al.

    Cellular senescence has been implicated in the pathophysiology of radiotherapy-associated bone loss. Based on our previous work, clearance of senescent cells using genetic and pharmacological tools alleviates the anomalies associated with radiation-associated bone deterioration. The pro-inflammatory senescence associated secretome referred to as senescence associated secretory phenotype (SASP), is a hallmark of cellular senescence. The modulation of SASP by senomorphic drugs, potentially can suppress the pro-inflammatory secretome of senescent cells, irrespective of the underlying senescence mechanism. In this study, we tested a senomorphic drug, ruxolitinib, a Janus kinase inhibitor (JAKi), during acute and chronic radiotherapy related effects on the bone. Our clinical data indicate an early increase in several pro-inflammatory SASP proteins following radiotherapy of spinal metastasis in prostate cancer patients. Longitudinal assessment of SASP-related genes confirmed this acute elevation in several SASP markers in systemic circulation following irradiation of male mouse femurs. In studies done in male mice, following three preclinical radiotherapy regimens of 30 Gy (5× 6 Gy), 60 Gy (5× 12 Gy) and a single dose of 24 Gy, suppression of SASP by JAKi was efficacious in suppressing radiation-induced bone damage. In comparison and as shown before, the senolytic combination of D+Q was also able to alleviate radiation-associated bone loss. Early and intermittent suppression of SASP using JAK inhibitors in male mice alleviated chronic bone deterioration, diminished telomere dysfunction, lowered senescence and SASP marker expression, and reduced bone-marrow adiposity. Overall, our study shows that early targeting of SASP proteins could be a potential therapeutic to prevent radiotherapy-related chronic bone loss and risk of fractures.

  • The Rochester Older Adult Registry (ROAR): Catalyzing Inclusion of Older Adults in Research

    by Maria Mendoza De la Garza, Allyson K. Palmer, Hawea H. Derauf, Michael A. Golafshar, Tammy Evans, Brandon P. Verdoorn, Robert J. Pignolo

  • Open Access

    Incidence of RSV-Acute Respiratory Infection in Adults 18-64 years with High-Risk Conditions: A Prospective Community-based Surveillance Study

    by Wendelyn Bosch, Katherine S King, Chung-Il Wi, Dave Watson, Colin L Colby, Traci L Natoli, Brandon H Hidaka, Randy Foss, Lisa J Speiser, Pouya Saeedi, et al.

    Background: Data on respiratory syncytial virus (RSV) acute respiratory infection (ARI) among community-dwelling U.S. adults aged 18-64 years, particularly those with high-risk conditions (HRC), remain limited. This study estimated incidence and attack rates of RSV-ARI and RSV lower respiratory tract disease (LRTD) in adults with and without HRCs. Methods: A multi-state, community-based prospective cohort of adults aged 18–64 years with and without HRCs was followed from October 2022 to September 2024. Incidence rates and annual attack rates of RSV-ARI and RSV-LRTD were calculated by HRC presence and age group. Results: Of 3,375 adults with at least one HRC, the RSV-ARI incidence rate was 17.9 per 1,000 person-years (attack rates: year-1, 1.87%; year-2, 1.56%), compared with 14.8 per 1,000 person-years (year-1, 1.33%; year-2, 1.50%) among adults without HRCs. RSV-LRTD incidence was 10.0 per 1,000 person-years in adults with HRCs versus 5.7 per 1,000 person-years in those without. Asthma, congenital immunodeficiency, and immunosuppressive medication use were associated with increased incidence of RSV-ARI and RSV-LRTD; while adults with solid organ transplant and chronic kidney disease had a significantly higher incidence rate of RSV-LRTD compared to those without these conditions. Adults aged 18–49 years with HRCs had significantly higher RSV-LRTD incidence (9.6 vs. 4.3 per 1,000 person-years). After adjustment for age and sex, having ≥1 HRC was associated with a 62% increased RSV-LRTD risk, rising to 117% among adults aged 18–49 years. Conclusions: Adults with HRCs—particularly asthma, congenital immunodeficiency, chronic kidney disease, immunosuppressive medication use, and solid organ transplant—experienced higher RSV-ARI and RSV-LRTD incidence. The elevated RSV-LRTD burden was most pronounced in adults aged 18–49 years with HRCs.


  • Open Access

    Primary Cilia Are Required for Efficient BMP Signaling in Traumatic Heterotopic Ossification

    by Xinyuan Yuan, Saman Toutounchi, Susan F. Law, David Achudhan, Abhishek Chandra, Kai He, Yingshu Cao, Jinghua Hu, Robert J. Pignolo, Haitao Wang

    Background/Objectives: Heterotopic ossification (HO), the aberrant formation of bone within soft tissues, arises either from rare genetic mutations or more commonly from traumatic insults. It is a major cause of morbidity not only in individuals harboring causative mutations, but also in those undergoing musculoskeletal surgery or trauma and in soldiers sustaining blast or burn injuries. Bone morphogenetic protein (BMP) signaling is a central driver of both hereditary and acquired forms of HO. Primary cilia are nonmotile, antenna-like organelles that extend from the cell surface and serve as crucial sensory and signaling hubs by concentrating key pathway components within a confined volume at the ciliary tip. However, their functional role in the pathogenesis of traumatic HO remains poorly understood. Methods: We investigate the role of primary cilia in traumatic HO using a genetically modified mouse model and cellular model. Results: We demonstrate that BMP signaling is attenuated when primary cilia function is disrupted. Both ciliation frequency and ciliary length were reduced in Scleraxis-CreERT2; Intraflagellar transport 88 floxed/floxed (Scx-CreERT2;Ift88fl/fl) tenocytes. Deletion of Ift88 effectively suppressed pathological BMP signaling and inhibited HO formation. Conclusions: These findings establish that functional primary cilia are required for traumatic HO development and highlight ciliary regulation as a potential therapeutic avenue for preventing or mitigating post-traumatic HO.

  • Open Access

    Suppression of early pro-inflammatory senescent signature post-radiotherapy mitigates chronic bone damage

    by David Achudhan, Jacob Orme, Ritika Sharma, Aqsa Komel, Khubaib Gul Khan, Thomas A. White, Nathan K. LeBrasseur, Sundeep Khosla, Sean S. Park, Robert J. Pignolo, et al.

    Cellular senescence has been implicated in the pathophysiology of radiotherapy-related bone loss. Based on our previous work, clearance of senescent cells using genetic and pharmacological tools alleviates the anomalies associated with radiation-associated bone deterioration. The pro-inflammatory senescence associated secretome referred to as senescence associated secretory phenotype (SASP), is a hallmark of cellular senescence. The modulation of SASP by senomorphic drugs, potentially can suppress the pro-inflammatory secretome of senescent cells, irrespective of the underlying senescence mechanism. In this study we tested a senomorphic drug, ruxolitinib, a Janus kinase inhibitor (JAKi), during acute and chronic radiotherapy related effects on the bone. Our clinical data indicate an early increase in several pro-inflammatory SASP proteins following radiotherapy of spinal metastasis in prostate cancer patients. Longitudinal assessment of SASP-related genes confirmed this acute elevation in several SASP markers in systemic circulation following irradiation of mouse femurs. In a proof-of-concept study, following two preclinical radiotherapy regimens of cumulative doses of 30Gy (5 x 6Gy) and 60Gy (5 x 12Gy), a senomorphic approach of JAKi treatment was more effective in alleviating radiation-related bone loss compared to the senolytic cocktail of D+Q. Early and intermittent suppression of SASP using JAK inhibitors alleviated chronic bone deterioration, diminished telomere dysfunction, lowered senescence and SASP marker expression, reduced bone-marrow adiposity, and mitigated radiation related lymphatic impairment. Overall, our study shows that early targeting of SASP proteins could be a potential therapeutic to prevent radiotherapy-related chronic bone loss and risk of fractures. Lay Summary: Radiotherapy as part of cancer treatment is correlated with an acute increase in senescent cells. Here we show that the pro-inflammatory senescence associated secretory phenotype (SASP) becomes much more prominent soon after radiotherapy in both patients and mice. Suppression of the SASP using a Janus kinase inhibitor, ruxolitinib, reduced the overall senescent cell burden, improved bone architecture by promoting bone formation, reduced bone marrow adiposity, and mitigated radiation-induced lymphatic impairment. Overall, these findings suggest that early inhibition of the SASP may help mitigate several bone anomalies and prevent long-term bone loss and fractures after radiotherapy. Graphical


  • Scoliosis in Fibrodysplasia Ossificans Progressiva

    by Zaid Elsabbagh, Myung-Jin Cha, Robert J. Pignolo, Frederick S. Kaplan, Paul D. Sponseller

    Case: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by progressive heterotopic ossification. Scoliosis may develop and progress rapidly, especially during adolescence. We report 4 patients with FOP and scoliosis during early adolescence: A 12-year-old girl underwent T4-S2 posterior spinal fusion (PSF); another 12-year-old girl underwent T4-S2 PSF; a 13-year-old boy underwent T3-L4 PSF; and a 14-year-old girl was managed nonoperatively because the complex deformity and ankylosed shoulders could not be adequately balanced with surgery. Conclusion: In patients with FOP, surgical intervention can reduce thoracic deformity and improve pulmonary function but carries substantial risks, including heterotopic ossification.


  • Open Access

    Comprehensive healthspan assessments and influence of sex as a biological variable in aging rats

    by Abhishek Chandra, Zaira Aversa, Xu Zhang, Joshua N. Farr, Achudhan David, Ritika Sharma, Tamara Tchkonia, James L. Kirkland, Paul D. Robbins, Laura J. Niedernhofer, et al.

    Rats share a significant amount of genetic and physiological similarity with humans. Many biological processes and pathways are conserved between rats and humans, making rats a suitable model for studying various aspects of human health and disease. Using rats as an aging model offers a more ethical alternative to using larger, longer-lived animals like primates. Rats are easier to handle in laboratory settings, as compared to non-human primates, both of which have physiological functions like humans. To date, there are very few studies which have comprehensively studied age-related changes in rat physiology. Here we present a longitudinal assessment of several aspects of Brown-Norway rat physiology and histopathology using molecular and functional assessments at 6-, 17- and 27 months of age. Our studies thus provide age-related healthspan parameters, which can be used as reference for genetic or pharmacological rat models of aging.